December 31, (In thousands, except share and per share data) 2013 2012 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 25,088 $ 19,226 Accounts receivable, net of allowance for doubtful accounts of $2,872 and $3,516 at 2013 and 2012, respectively 201,322 184,774 Inventories 46,821 49,265 Prepaid expenses 13,128 14,959 Income tax receivable 5,294 17,943 Other current assets 12,215 10,740 TOTAL CURRENT ASSETS 303,868 296,907 PROPERTY, PLANT AND EQUIPMENT, net 138,824 125,418 INTANGIBLES, net 10,949 8,721 GOODWILL 163,337 163,337 DEFERRED TAX ASSETS, net 4,452 13,224 OTHER ASSETS 39,580 28,909 TOTAL ASSETS $ 661,010 $ 636,516 LIABILITIES AND EQUITY CURRENT LIABILITIES: Accounts payable $ 50,821 $ 55,168 Accrued payroll and related costs 38,969 34,919 Taxes other than payroll and income 6,979 11,787 Unearned revenues 10,887 13,868 Income taxes payable 14,462 9,542 Other accrued expenses 13,657 15,226 TOTAL CURRENT LIABILITIES 135,775 140,510 LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS 267,002 234,033 DEFERRED COMPENSATION 38,014 28,112 DEFERRED TAX LIABILITIES, net 8,870 6,777 OTHER LONG-TERM LIABILITIES 41,960 39,171 COMMITMENTS AND CONTINGENCIES EQUITY: Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding — — Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 46,750,002 issued and 45,101,389 outstanding at 2013 and 47,899,584 issued and 46,349,411 outstanding at 2012 1,203 1,233 Additional paid-in capital — — Retained earnings 415,930 361,255 Accumulated other comprehensive income (loss) (8,626) (8,413) Treasury shares (at cost), 1,648,613 at 2013 and 1,550,173 at 2012  (245,184) (171,845) Total Core Laboratories N.V. shareholders’ equity 163,323 182,230 Non-controlling interest 6,066 5,683 TOTAL EQUITY 169,389 187,913 TOTAL LIABILITIES AND EQUITY $ 661,010 $ 636,516 The accompanying notes are an integral part of these Consolidated Financial Statements. 34 CORE LABORATORIES N.V.  CONSOLIDATED BALANCE SHEETS